Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 4 , Pages 333-344 , April 2010

Cognitive and Psychiatric Predictors to Psychosis in Velocardiofacial Syndrome: A 3-Year Follow-Up Study

,Accepted 5 January 2010.

References 

  1. Robin NH, Shprintzen RJ. Defining the clinical spectrum of deletion 22q11.2. J Pediatr. 2005;147:90–96
  2. Botto LD, May K, Fernhoff PM, et al. A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics. 2003;112:101–107
  3. Morrow B, Goldberg R, Carlson C, et al. Molecular definition of the 22q11 deletions in velo-cardio-facial syndrome. Am J Hum Genet. 1995;56:1391–1403
  4. Shprintzen R, Higgins AM, Antshel K, et al. Velo-cardio-facial syndrome. Curr Opin Pediatr. 2005;17:725–730
  5. Antshel KM, AbdulSabur N, Roizen N, Fremont W, Kates WR. Sex differences in cognitive functioning in velocardiofacial syndrome (VCFS). Dev Neuropsychol. 2005;28:849–869
  6. Campbell LE, Daly E, Toal F, et al. Brain and behaviour in children with 22q11.2 deletion syndrome: a volumetric and voxel-based morphometry MRI study. Brain. 2006;129:1218–1228
  7. Shashi V, Keshavan MS, Howard TD, et al. Cognitive correlates of a functional COMT polymorphism in children with 22q11.2 deletion syndrome. Clin Genet. 2006;69:234–238
  8. Oskarsdottir S, Belfrage M, Sandstedt E, Viggedal G, Uvebrant P. Disabilities and cognition in children and adolescents with 22q11 deletion syndrome. Dev Med Child Neurol. 2005;47:177–184
  9. Swillen A, Devriendt K, Legius E, et al. Intelligence and psychosocial adjustment in velocardiofacial syndrome: a study of 37 children and adolescents with VCFS. J Med Genet. 1997;34:453–458
  10. Feinstein C, Eliez S, Blasey C, Reiss AL. Psychiatric disorders and behavioral problems in children with velocardiofacial syndrome: usefulness as phenotypic indicators of schizophrenia risk. Biol Psychiatry. 2002;51:312–318
  11. Woodin M, Wang PP, Aleman D, McDonald-McGinn D, Zackai E, Moss E. Neuropsychological profile of children and adolescents with the 22q11.2 microdeletion. Genet Med. 2001;3:34–39
  12. Moss EM, Batshaw ML, Solot CB, et al. Psychoeducational profile of the 22q11.2 microdeletion: a complex pattern. J Pediatr. 1999;134:193–198
  13. Wang PP, Woodin MF, Kreps-Falk R, Moss EM. Research on behavioral phenotypes: velocardiofacial syndrome (deletion 22q11.2). Dev Med Child Neurol. 2000;42:422–427
  14. Lajiness-O'Neill R, Beaulieu I, Titus JB, et al. Memory and learning in children with 22q11.2 deletion syndrome: evidence for ventral and dorsal stream disruption?. Child Neuropsychol. 2005;11:55–71
  15. Majerus S, Glaser B, Van der Linden M, Eliez S. A multiple case study of verbal short-term memory in velo-cardio-facial syndrome. J Intellect Disabil Res. 2006;50:457–469
  16. Sobin C, Kiley-Brabeck K, Daniels S, et al. Neuropsychological characteristics of children with the 22q11 deletion syndrome: a descriptive analysis. Child Neuropsychol. 2005;11:39–53
  17. Bearden CE, Woodin MF, Wang PP, et al. The neurocognitive phenotype of the 22q11.2 deletion syndrome: selective deficit in visual-spatial memory. J Clin Exp Neuropsychol. 2001;23:447–464
  18. Swillen A, Vandeputte L, Cracco J, et al. Neuropsychological, learning and psychosocial profile of primary school aged children with the velo-cardio-facial syndrome (22q11 deletion): evidence for a nonverbal learning disability?. Child Neuropsychol. 1999;5:230–241
  19. Lewandowski KE, Shashi V, Berry PM, Kwapil TR. Schizophrenic-like neurocognitive deficits in children and adolescents with 22q11 deletion syndrome. Am J Med Genet B Neuropsychiatr Genet. 2007;144:27–36
  20. De Smedt B, Swillen A, Devriendt K, et al. Mathematical disabilities in young primary school children with velo-cardio-facial syndrome. Genetic Counsel. 2006;17:259–280
  21. Simon T, Burg-Malki M, Gothelf D. Cognitive and behavioral characteristics of children with 22q11.2 deletion syndrome. In:  Ross JL,  Mazzocco MMM editor. Neurogenetic Developmental Disorders: Manifestation and Identification in Childhood. Cambridge, MA: MIT Press; 2007;p. 297–334
  22. Simon T, Bearden CE, Mc-Ginn DM, Zackai E. Visuospatial and numerical cognitive deficits in children with chromosome 22q11.2 deletion syndrome. Cortex. 2005;41:145–155
  23. Bish JP, Chiodo R, Mattei V, Simon TJ. Domain specific attentional impairments in children with chromosome 22q11.2 deletion syndrome. Brain Cogn. 2007;64:265–273
  24. Niklasson L, Rasmussen P, Oskarsdottir S, Gillberg C. Attention deficits in children with 22q.11 deletion syndrome. Dev Med Child Neurol. 2005;47:803–807
  25. Kiley-Brabeck K, Sobin C. Social skills and executive function deficits in children with the 22q11 deletion syndrome. Appl Neuropsychol. 2006;13:258–268
  26. Lajiness-O'Neill R, Beaulieu I, Asamoah A, et al. The neuropsychological phenotype of velocardiofacial syndrome (VCFS): relationship to psychopathology. Arch Clin Neuropsychol. 2006;21:175–184
  27. Gothelf D, Hoeft F, Hinard C, et al. Abnormal cortical activation during response inhibition in 22q11.2 deletion syndrome. Hum Brain Mapp. 2007;28:533–542
  28. Sobin C, Kiley-Brabeck K, Karayiorgou M. Associations between prepulse inhibition and executive visual attention in children with the 22q11 deletion syndrome. Mol Psychiatry. 2005;10:553–562
  29. Antshel KM, Faraone SV, Fremont W, et al. comparing ADHD in velocardiofacial Syndrome to idiopathic ADHD: a preliminary study. J Atten Disord. 2007;11:64–73
  30. Antshel KM, Fremont W, Roizen NJ, et al. ADHD, major depressive disorder, and simple phobias are prevalent psychiatric conditions in youth with velocardiofacial syndrome. J Am Acad Child Adolesc Psychiatry. 2006;45:596–603
  31. Gothelf D, Gruber R, Presburger G, et al. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. J Clin Psychiatry. 2003;64:1163–1169
  32. Swillen A, Devriendt K, Legius E, et al. The behavioural phenotype in velo-cardio-facial syndrome (VCFS): from infancy to adolescence. Genet Couns. 1999;10:79–88
  33. Vogels A, Verhoeven WM, Tuinier S, et al. The psychopathological phenotype of velo-cardio-facial syndrome. Ann Genet. 2002;45:89–95
  34. Antshel KM, Aneja A, Strunge L, et al. Autistic spectrum disorders in velo-cardio facial syndrome (22q11.2 deletion). J Autism Dev Disord. 2007;37:1776–1786
  35. Vorstman JA, Morcus ME, Duijff SN, et al. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. J Am Acad Child Adolesc Psychiatry. 2006;45:1104–1113
  36. Papolos DF, Faedda GL, Veit S, et al. Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder?. Am J Psychiatry. 1996;153:1541–1547
  37. Murphy KC. Schizophrenia and velo-cardio-facial syndrome. Lancet. 2002;359:426–430
  38. Murphy KC, Owen MJ. Velo-cardio-facial syndrome: a model for understanding the genetics and pathogenesis of schizophrenia. Br J Psychiatry. 2001;179:397–402
  39. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry. 1999;56:940–945
  40. Bassett AS, Chow EW, AbdelMalik P, Gheorghiu M, Husted J, Weksberg R. The schizophrenia phenotype in 22q11 deletion syndrome. Am J Psychiatry. 2003;160:1580–1586
  41. Usiskin SI, Nicolson R, Krasnewich DM, et al. Velocardiofacial syndrome in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry. 1999;38:1536–1543
  42. Baker KD, Skuse DH. Adolescents and young adults with 22q11 deletion syndrome: psychopathology in an at-risk group. Br J Psychiatry. 2005;186:115–120
  43. Einfeld SL, Tonge BJ. Population prevalence of psychopathology in children and adolescents with intellectual disability: II. Epidemiological findings. J Intellect Disabil Res. 1996;40:99–109
  44. Diamond A, Briand L, Fossella J, Gehlbach L. Genetic and neurochemical modulation of prefrontal cognitive functions in children. Am J Psychiatry. 2004;161:125–132
  45. Goldman D, Weinberger DR, Malhotra AK, Goldberg TE. The role of COMT Val158Met in cognition. Biol Psychiatry. 2009;65:e1–e2author reply e3-4
  46. Lewandowski KE. Relationship of catechol-O-methyltransferase to schizophrenia and its correlates: evidence for associations and complex interactions. Harvard Rev Psychiatry. 2007;15:233–244
  47. Gothelf D, Feinstein C, Thompson T, et al. Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. Am J Psychiatry. 2007;164:663–669
  48. Bearden CE, Jawad AF, Lynch DR, et al. Effects of a functional COMT polymorphism on prefrontal cognitive function in patients with 22q11.2 deletion syndrome. Am J Psychiatry. 2004;161:1700–1702
  49. Bassett AS, Caluseriu O, Weksberg R, Young DA, Chow EW. Catechol-O-methyl transferase and expression of schizophrenia in 73 adults with 22q11 deletion syndrome. Biol Psychiatry. 2007;61:1135–1140
  50. van Amelsvoort T, Zinkstok J, Figee M, et al. Effects of a functional COMT polymorphism on brain anatomy and cognitive function in adults with velo-cardio-facial syndrome. Psychol Med. 2008;38:89–100
  51. McGorry PD, Nelson B, Amminger GP, et al. Intervention in individuals at ultra high risk for psychosis: a review and future directions. J Clin Psychiatry. 2009;70:1206–1212
  52. Kim WJ. Child and adolescent psychiatry workforce: a critical shortage and national challenge. Acad Psychiatry. 2003;27:277–282
  53. Kates WR, Antshel KM, Abdulsabur N, et al. A gender-moderated effect of a functional COMT polymorphism on prefrontal brain morphology and function in velo-cardio-facial syndrome (22q11.2 deletion syndrome). Am J Med Genet B Neuropsychiatr Genet. 2006;141:274–280
  54. Wechsler D. Wechsler Intelligence Scale for Children–Third edition. San Antonio, TX: Psychological Corporation; 1991;
  55. Wechsler D. Wechsler Adult Intelligence Scale–3rd edition. San Antonio, TX: Psychological Corporation; 1993;
  56. Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 3 ed.. Oxford University Press; 2006;
  57. Gold J. Schizophrenia and intellectual decline. Am J Psychiatry. 1998;155:1633–1634author reply 1636-1637
  58. Russell AJ, Munro JC, Jones PB, Hemsley DR, Murray RM. Schizophrenia and the myth of intellectual decline. Am J Psychiatry. 1997;154:635–639
  59. Wechsler D. Wechsler Individual Achievement Test–Second edition. San Antonio, TX: Psychological Corporation; 2002;
  60. Gordon M. The Gordon Diagnostic System. DeWitt, NY: Gordon Systems; 1983;
  61. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. Wisconsin Card Sorting Test Manual: Revised and Expanded. Odessa, FL: Psychological Assessment Resources; 1993;
  62. Delis D, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test–Children's Version. San Antonio, TX: Psychological Corporation; 1994;
  63. Davis HR. Colorado Assessment Tests–Visual Span Test. Boulder, CO: Colorado Assessment Tests; 1998;
  64. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980–988
  65. APA. DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000;
  66. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29:703–715
  67. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8:470–484
  68. Reynolds CR, Kamphaus RW. Behavior Assessment Scales for Children (BASC). Circle Pines, MN: American Guidance Service; 1992;
  69. Lambert D. Zero-inflated Poisson regression with an application to defects in manufacturing. Technometrics. 1992;34:1–14
  70. Brewer WJ, Francey SM, Wood SJ, et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry. 2005;162:71–78
  71. Hawkins KA, Addington J, Keefe RS, et al. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr Res. 2004;67:115–122
  72. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 1994;51:124–131
  73. Byrne M, Hodges A, Grant E, Owens DC, Johnstone EC. Neuropsychological assessment of young people at high genetic risk for developing schizophrenia compared with controls: preliminary findings of the Edinburgh High Risk Study (EHRS). Psychol Med. 1999;29:1161–1173
  74. Erlenmeyer-Kimling L, Roberts SA, Rock D, et al. Prediction from longitudinal assessments of high-risk children. In:  Lenzenweger MF,  Dworkin RH editor. Origins and Development of Schizophrenia: Advances in Experimental Psychopathology. Washington, DC: American Psychological Association; 1998;p. 427–445
  75. Seidman LJ, Giuliano AJ, Smith CW, et al. Neuropsychological functioning in adolescents and young adults at genetic risk for schizophrenia and affective psychoses: results from the Harvard and Hillside Adolescent High Risk Studies. Schizophr Bull. 2006;32:507–524
  76. Cosway R, Byrne M, Clafferty R, et al. Neuropsychological change in young people at high risk for schizophrenia: results from the first two neuropsychological assessments of the Edinburgh High Risk Study. Psychol Med. 2000;30:1111–1121
  77. Simon AE, Cattapan-Ludewig K, Zmilacher S, et al. Cognitive functioning in the schizophrenia prodrome. Schizophr Bull. 2007;33:761–771
  78. Hambrecht M, Lammertink M, Klosterkotter J, Matuschek E, Pukrop R. Subjective and objective neuropsychological abnormalities in a psychosis prodrome clinic. Br J Psychiatry Suppl. 2002;43:s30–s37
  79. Toomey R, Faraone SV, Seidman LJ, et al. Association of neuropsychological vulnerability markers in relatives of schizophrenic patients. Schizophr Res. 1998;31:89–98
  80. Cornblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull. 1994;20:31–46
  81. Cornblatt B, Obuchowski M, Schnur D, O'Brien JD. Hillside study of risk and early detection in schizophrenia. Br J Psychiatry Suppl. 1998;172:26–32
  82. Lencz T, Smith CW, McLaughlin D, et al. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry. 2006;59:863–871
  83. Wolf LE, Cornblatt BA, Roberts SA, Shapiro BM, Erlenmeyer-Kimling L. Wisconsin Card Sorting deficits in the offspring of schizophrenics in the New York High-Risk Project. Schizophr Res. 2002;57:173
  84. Hans SL, Auerbach JG, Styr B, Marcus J. Offspring of parents with schizophrenia: mental disorders during childhood and adolescence. Schizophr Bull. 2004;30:303–315
  85. Keshavan MS, Sujata M, Mehra A, Montrose DM, Sweeney JA. Psychosis proneness and ADHD in young relatives of schizophrenia patients. Schizophr Res. 2003;59:85–92
  86. Ross RG, Compagnon N. Diagnosis and treatment of psychiatric disorders in children with a schizophrenic parent. Schizophr Res. 2001;50:121–129
  87. Welham J, Scott J, Williams G, et al. Emotional and behavioural antecedents of young adults who screen positive for non-affective psychosis: a 21-year birth cohort study. Psychol Med. 2009;39:625–634
  88. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res. 2004;68:37–48
  89. Miller TJ, McGlashan TH, Woods SW, et al. Symptom assessment in schizophrenic prodromal states. Psychiatr Q. 1999;70:273–287
  90. Green T, Gothelf D, Glaser B, et al. Psychiatric disorders and intellectual functioning throughout development in velocardiofacial (22q11.2 deletion) syndrome. J Am Acad Child Adolesc Psychiatry. 2009;48:1060–1068
  91. Shochet IM, Homel R, Cockshaw WD, Montgomery DT. How do school connectedness and attachment to parents interrelate in predicting adolescent depressive symptoms?. J Clin Child Adolesc Psychol. 2008;37:676–681
  92. Van Voorhees BW, Paunesku D, Kuwabara SA, et al. Protective and vulnerability factors predicting new-onset depressive episode in a representative of U.S. adolescents. J Adolesc Health. 2008;42:605–616
  93. Hurtig T, Ebeling H, Taanila A, et al. ADHD symptoms and subtypes: relationship between childhood and adolescent symptoms. J Am Acad Child Adolesc Psychiatry. 2007;46:1605–1613
  94. Niklasson L, Rasmussen P, Oskarsdottir S, Gillberg C. Autism, ADHD, mental retardation and behavior problems in 100 individuals with 22q11 deletion syndrome. Res Dev Disabil. 2009;30:763–773
  95. van Amelsvoort T, Henry J, Morris R, et al. Cognitive deficits associated with schizophrenia in velo-cardio-facial syndrome. Schizophr Res. 2004;70:223–232
  96. Goldman-Rakic PS, Muly EC, Williams GV. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev. 2000;31:295–301
  97. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol. 2004;74:1–58

 This article was reviewed under and accepted by Ad Hoc Editor Daniel S. Pine, M.D.

 This work was funded by National Institute of Mental Health grants MH64824 and MH65481 to Wendy Kates.

 Disclosure: Dr. Faraone, in the past year, has received consulting fees and has been on Advisory Boards for Eli Lilly, Ortho-McNeil, and Shire Development, and has received research support from Eli Lilly, Pfizer, Shire, and the National Institutes of Health. In previous years, Dr. Faraone has received consulting fees or has been on advisory boards, or has been a speaker for the following sources: Shire, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly. In previous years he has received research support from Eli Lilly, Shire, Pfizer, and the National Institutes of Health. Drs. Antshel, Shprintzen, Fremont, and Kates, and Ms. Higgins report no biomedical financial interests or potential conflicts of interest.

PII: S0890-8567(10)00086-9

doi: 10.1016/j.jaac.2010.01.010

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 4 , Pages 333-344 , April 2010

Article Tools